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Enterococcus faecalis is one of the most signiﬁcant pathogen in both
nosocomial and community-acquired infections. Reduced susceptibility to anti-
biotics is in part due to efﬂux pumps. This study was conducted on 80 isolates
of E. faecalis isolated from outpatients with urinary tract infection during a period
of 1 year from April 2014 to April 2015. The antibiotic susceptibility patterns of
isolates were determined by the disk diffusion method and presence of efrA and
efrB genes was detected by PCR and sequencing. Minimum inhibitory concen-
trations (MICs) to ciproﬂoxacin (CIP) were measured with and without carbonyl
cyanide 3-chlorophenylhydrazone (CCCP) by broth microdilution. The highest
resistance rate was observed to erythromycin (83.3%) and the prevalence of efrA
and efrB genes in all E. faecalis isolates was 100%. This study showed that 9 out
of 13 (69.2%) ciproﬂoxacin-resistant isolates became less resistant at least
fourfolds to CIP in the presence of efﬂux pump inhibitor. Our result showed
that CCCP as an efﬂux inhibitor can increase effect of CIP as an efﬁcient
antibiotic and it is suggested that efrAB efﬂux pumps are involved in resistance
to ﬂuoroquinolone.
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Introduction
Gram-positive organisms are responsible for a number of the most severe
human infections [1]. One of the most signiﬁcant of such bacteria is Enterococcus
faecaliswhich is a common contributor agent to both nosocomial and community-
acquired infections in patients, including bacteremia, surgical site infections, and
urinary tract infections (UTIs) due to its multidrug resistance (MDR) and
colonizing capability. However, their particular pathogenic mechanisms are not
completely clariﬁed [2–4]. E. faecalis has been graded among the most prominent
causes of UTIs, which are predominantly caused by E. faecalis [5, 6]. These
acquired mechanisms of resistance consist of spontaneous mutation along with
genetic exchange with other bacteria in the environment through horizontal gene
transfer. Moreover, E. faecalis is inherently more resistant to a number of
antimicrobials in comparison with the majority of Gram-positive bacteria [7].
Resistance to the ﬁrst-line antimicrobial agents makes the treatments difﬁcult.
Such drug resistance can arise from the activity of membrane-based efﬂux
proteins, and henceforth referred to as “pumps.” Transportation processes irrele-
vant to drug resistance, including efﬂux, are used by all bacteria to obtain
nutrients. While bacteria normally use efﬂux as a transportation process to obtain
nutrients, they can take advantage of the same mechanism to efﬂux antibiotics [1].
Ciproﬂoxacin (CIP), a ﬂuoroquinolone, is a broad-spectrum antimicrobial that is
important in the treatment of a wide range of clinical infections [8]. Although
principal mechanisms of resistance to β-lactams, ﬂuoroquinolones, aminoglyco-
sides, and vancomycin are well documented, relatively little is known about drug
efﬂux pumps in E. faecalis [9]. The most extensively studied efﬂux pumps in E.
faecalis are a homolog of NorA, EmeA, a member of the major facilitator
superfamily (MFS), and efrAB belonging to the ATP-binding cassette (ABC)
superfamily of multidrug efﬂux transporters [10]. The signiﬁcance of E. faecalis is
partly due to the existence of MDR efﬂux pumps such as EmeA which belongs to
the MFS and the ABC-type MDR transporters [11]. A type of ABC multidrug
efﬂux pump named efrAB was identiﬁed in E. faecalis [12]. The heterodimeric
ABC transporter efrAB has been suggested to be an MDR pump, which transports
norﬂoxacin and acriﬂavine when overexpressed in Escherichia coli [13], but its
function in E. faecalis has not been studied by a respective gene deletion [9]. In this
work, we explored the general role of efrAB efﬂux pump inhibitor, carbonyl
cyanide 3-chlorophenylhydrazone (CCCP), in the minimum inhibitory concentra-
tion (MIC) of CIP in resistant E. faecalis isolated from clinical samples. Inhibition
of efﬂux pump is a valuable alternative to decrease the susceptibility of
resistant E. faecalis to commonly used clinical antibiotics. Moreover, a detailed
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understanding of the antibiotic resistance and the underlying mechanisms in
E. faecalis is critical to the management of antimicrobial resistance problem in
clinical care, by using novel management tactics such as efﬂux pumps inhibitors
to control resistance to several antibiotics.
Objectives
There are a number of studies on ﬂuoroquinolones resistance in clinical
isolates of E. faecalis from Iranian populations, but this is the ﬁrst study about the
role of efrAB efﬂux pump in resistance to ﬂuoroquinolones of E. faecalis isolated
from clinical samples. So, the aim of this study was to investigate the inﬂuence of
active efﬂux system on CIP resistance in clinical isolates of E. faecalis using the
efﬂux pump inhibitor, CCCP.
Materials and Methods
Bacterial strains and media
This study was conducted on 80 isolates of E. faecalis isolated from
outpatients with UTI infection during a period of 1 year from April 2014 to
March 2015. Isolated samples were processed immediately after collection for
phenotypic detection of E. faecalis by standard protocols based on Gram staining,
catalase test, bile solubility, growth in sodium chloride, bile esculin test, and sugar
fermentation tests [14]. All strains were maintained and stored in brain–heart
infusion (BHI) broth (Merck, England) containing 20% glycerol at −80 °C. For
routine use, enterococcal strains were cultured on BHI broth at 37 °C. The PCR
assay was carried out by speciﬁc primers to conﬁrm the E. faecalis isolates (see the
“Molecular examinations” section).
Antibiotic susceptibility testing
The antibiotic susceptibility patterns of E. faecalis isolates were determined
by the disk diffusion method according to Clinical and Laboratory Standard
Institute guidelines (CLSI) [15]. Antimicrobial disks (Mast Group Ltd., United
Kingdom) were used to determine the susceptibility of enterococcal isolates to
penicillin G (10 μg), ampicillin (10 μg), vancomycin (30 μg), tetracycline (30 μg),
minocycline (30 μg), CIP (5 μg), levoﬂoxacin (5 μg), gatiﬂoxacin (5 μg),
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nitrofurantoin (300 μg), gentamicin (120 μg), and linezolid (30 μg). After
incubation at 37 °C for 24 h in Mueller–Hinton agar (Merck, Germany), the
diameter of growth inhibition around each disk was measured. E. faecalis ATCC
29212 was used as a reference strain.
Molecular examinations
Extraction of the genomic DNA was performed using the High Pure PCR
Template Preparation Kit (Roche, Germany), with some modiﬁcations. The
bacterial pellet was mixed with 200 μL PBS, digested in 5 μL lysozyme, and
incubated at 37 °C for 15 min. The mixture was then lysed using a short incubation
with a lysis buffer and proteinase K. The solution was then transferred to a spin
column to remove any contaminating cellular components. Finally, the DNA was
eluted using an elution buffer at 70 °C. PCR was carried out in a total volume of
25 μL Master mix 2× (Sinaclon, Iran; CAT. NO. PR901638) containing 10 pmol
of primers, 100 ng of genomic DNA, 0.4 mM of each of four dNTPs, 3 mM
MgCl2, and 0.08 U of Taq DNA polymerase. The primer sequences used
were ddlE1 (ATCAAGTACAGTTAGTCTTTATTAG) and ddIE2 (ACGATT-
CAAAGCTAACTGAATCAGT) for E. faecalis isolates [16]. PCR was performed
in a thermal cycler (Eppendorf Master cycler, Germany) under the following
conditions: initial denaturation step at 94 °C for 5 min followed by 36 cycles,
including denaturation at 94 °C for 1 min, annealing at 49 °C (for ddlE) and 72 °C
for 1 min followed by a ﬁnal extension at 72 °C for 10 min to ensure full extension
of the PCR products. The PCR ampliﬁcation products were identiﬁed through
electrophoresis in a 1% agarose gel followed by staining with red safe solution and
a 100-bp DNA ladder (Fermentas, Germany). The results were visualized under a
UV transilluminator. Positive control efrAB from E. faecalis was isolated from
clinical samples (positive control efrAB from Bioneer Company, Korea).
PCR ampliﬁcation of efrA and efrB genes
The presence of efrA and efrB genes was detected by PCR using the
sequence-speciﬁc primer sets described in Table I. PCR was carried out in a
total volume of 25 μL Master mix 2× (Sinaclon) containing 10 pmol of
primers, 100 ng of genomic DNA, 0.4 mM of each of four dNTPs, 3 mM
MgCl2, and 0.08 U of Taq DNA polymerase. The cycling program was
adjusted as follows: initial denaturation at 94 °C for 5 min followed by
30 cycles of 94 °C for 45 s, 57 °C for 45 s, 72 °C for 45 s, and a ﬁnal extension
at 72 °C for 5 min [10].
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Sequencing
The PCR puriﬁcation kit (Bioneer Company) was used to purify PCR
products and sequencing was performed by the Bioneer Company. The nucleotide
sequences were analyzed with the Chromas 1.45 software and BLAST program
from the National Center for Biotechnology Information website (http://www.
ncbi.nlm.nih.gov/BLAST).
Treatment of the efﬂux pump inhibitor
The MICs of CIP were deﬁned in Mueller–Hinton broth according to CLSI
[15], using the broth microdilution method in 96-well ﬂat bottom plates. We made
two different conditions for each sample. One of the plates contained only CIP and
the other plate contained CCCP (Sigma-Aldrich, Shanghai, China) as well as CIP.
A set of different concentrations was prepared for each of the two conditions using
serial dilution. Similar amounts of bacterial suspensions were further added to
each sample. The ﬁnal concentration of CCCP ranged 25 μg/mL and after
incubation for 24 h, the MICs were recorded as the lowest concentration of test
compound that was able to inhibit the visual growth [17]. Then, MIC for CIP was
determined again for each sample used. A plate containing (25 μg/mL) CCCP
without antibiotics was used as control. A reduction of more than fourfolds in the
MIC following the addition of CCCP showed that an efﬂux pump can extrude
antibiotics [18].
Statistical analysis
This research was a descriptive-application study. SPSS 16 software was
used for statistical analyses. The P value and conﬁdence of intervals were <0.05
and 95%, respectively.
Table I. Details of primers used in this study
Genes Primers (5′–3′)
PCR
product size (bp) Reference
efrA F: 5′-ACGCCAGTGATGTTTATTGC-3′ 543 This study
R: 5′-ACGAATAGCTGGTTCCATGT-3′
efrB F: 5′-AGTTACTATGTGGTTGCTGG-3′ 439 This study
R: 5′-GGACATCACTACGGTTCATT-3′
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Results
Epidemiological characteristics
Out of 80 E. faecalis isolated samples from patients, 41 patients were
females (51.2%) and 39 patients were males (48.8%). The mean age of the
patients was 21 years (range: 2–84 years old). All the subjects had chief
complaints of UTI.
Bacterial isolates and antimicrobial susceptibility test
In a year period, 80 strains of E. faecalis were isolated from outpatients with
UTI infection. Using biochemical tests and conﬁrmatory PCR assays, we deter-
mined that all the strains (100%) were E. faecalis. The highest resistance rate was
observed in erythromycin (83.3%). The antibiotic resistance proﬁles of the strains
are summarized in Figure 1. The initial results of CIP susceptibility test using the
disk agar diffusion method revealed that 13 out of 80 isolates (16.2%) were
resistant to CIP. The MIC for CIP in bacterial isolates is summarized in Table II.
According to the established breakpoint values suggested by CLSI [19], the
E. faecalis isolates with MIC ≥4 μg/mL are considered as CIP-resistant. In this
study, E. faecalis isolates had a CIP MIC range between 4 and 128 μg/mL or
greater (Table II), which means they are resistant to CIP.
Figure 1. Antimicrobial susceptibility test for E. faecalis isolates
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PCR ampliﬁcation and sequencing
The results of PCR ampliﬁcation indicate that prevalence of efrA and efrB
genes in all of isolates of E. faecalis is 100% (Figure 2). Sequencing of PCR
products displayed conserved regions for the restriction sequence efrA and efrB
genes which were further conﬁrmed by BLAST in NCBI. The nucleotide
sequence data described in this paper have been submitted to the GenBank
sequence database and have been assigned accession numbers KY131192 and
KY131193 for efrB gene and accession numbers KY244017 and KY244018 for
efrA gene (Figures 2 and 3). The sequences of the primers used in this study are
listed in Table I.
Table II. Effects of the efﬂux pump inhibitor on ciproﬂoxacin resistance
Isolates, no. (%)
MIC
(μg/mL)
MIC
(μg/mL)+CCCP
Reduction fold
in MIC+CCCP
1 (7.7) 4 1 2
1 (7.7) 8 8 0
4 (30.8) 32 1–8 2–10
4 (30.8) 64 4–32 2–6
1 (7.7) 128 64 2
1 (7.7) 256 256 0
Note: MIC: minimum inhibitory concentration; CCCP: carbonyl cyanide
3-chlorophenylhydrazone.
Figure 2. PCR ampliﬁcation of efrA genes. Lanes: M, 100 bp Plus DNA ladder (GeneRuler;
Fermentas); P, E. faecalis as positive control; 1–6, clinical isolates of E. faecalis
FIRST DETECTION OF efrAB IN IRAN 63
Acta Microbiologica et Immunologica Hungarica 66, 2019
Effects of the efﬂux pump inhibitor on CIP resistance
To determine the role of efﬂux pump in the CIP-resistant phenotypes in 80
E. faecalis isolates, we assessed the MIC of CIP in the presence of 25 μg/mL
CCCP and then compared the MICs with and without CCCP. The results showed
that 9 out of 13 (69.2%) CIP-resistant isolates became less resistant at least
fourfolds to CIP in the presence of efﬂux pump inhibitor (Table II).
Discussion
Bacteria have evolved sophisticated mechanisms of resistance comprising
drug efﬂux pumps that is adapted for a wide range of substrates, especially
antimicrobial drugs. Efﬂux-mediated resistance can be clinically relevant and
causes antibacterial therapy to be useless. It also provides starting point resistance
that leads to the emergence of additional resistance mechanisms, such as drug
inactivation or drug target modiﬁcation [20, 21]. The selection of efﬂux pump-
overproducing strains is inﬂuenced by bacterial exposure to antibacterials, and
limiting such exposure, including minimizing the antibacterial usage, would limit
the occurrence of efﬂux-mediated drug resistance [22, 23].
In this study, we investigated the prevalence of antibiotic resistance
especially to CIP among E. faecalis isolated from patients with UTIs.
Lee [24] showed that E. faecalis isolated from UTI subjects was 46% and
47% resistant to levoﬂoxacin and CIP, respectively [24]. However, the results of
this study revealed lower resistance to levoﬂoxacin and CIP (15% and 16.2%,
respectively). This differentiation can be attributed to the source of isolated
Figure 3. PCR ampliﬁcation of efrB gene. Lanes: M, 100 bp Plus DNA ladder (GeneRuler;
Fermentas); P, E. faecalis as positive control; 1–6, clinical isolates of E. faecalis
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specimens. In this study, the strains were isolated from UTI in outpatients, but in
the Korean study, the strains had been isolated from patients who usually had
multiple combined diseases for several years, according to the authors [24]. The
results of another study that was conducted by Seo and Lee [25] on E. faecalis
isolated from patients with chronic prostatitis showed 9.7% resistance to penicillin
[25], while the results of this study revealed 1.2% penicillin resistant. However,
the Seo and Lee’s study did not report any resistance to ampicillin, vancomycin, or
nitrofurantoin. These results are similar to this study and showed low prevalence
of resistance to ampicillin, vancomycin, or nitrofurantoin.
The analyzed results of antibiotic susceptibility test showed that E. faecalis
was highly resistant to tetracycline and minocycline. These are the effective
antibiotics against a wide range of microorganisms, which are cost-effective, and
therefore are frequently used as dominant antibiotics in poultry industry [26, 27].
Antibiotic consumption is one of the most important risk factors for distribution of
multidrug-resistant bacteria [28]. Broad-spectrum antimicrobial therapy is associ-
ated with increase of resistant bowel ﬂora during or after therapy [29]. Their
frequent use in the poultry industry leads us to the hypothesis that the increased
antibiotic resistance of the bacteria of normal intestinal ﬂora arises from poultry
treatment with tetracycline and minocycline. The fact that in this study, E. faecalis
isolated from patients with UTIs showed the most noticeable resistance to this
group of antibiotics and is consistent with Ayeni et al.’s [30] study in which
poultries were used as the samples.
Enterococcus is resistant to numerous antibiotics using efﬂux pump as a key
mechanism of resistance [7]. ABC transporters have important role in MDR
E. faecalis. efrAB is a heterodimeric ABC transporter, which can cause drug
resistance when efrA and efrB genes were expressed together [31]. We also
surveyed the existence of efrA and efrB genes in extracted DNA by PCR. The
results were higher than in the results of Valenzuela et al.’s [12] and Kang et al.’s
[32] studies. With the aim to explain that involvement of efrAB in CIP resistance,
we investigated that effect of CCCP as an efﬂux inhibitor on decrease of CIP MIC.
Our results showed that CCCP as an efﬂux inhibitor can increase the effect of CIP
as an efﬁcient antibiotic. In this study, the results of efﬂux pump inhibitor showed
decrease of CIP MIC from two- to tenfolds. The results of this study also suggest
that antibiotic efﬂux pumps are involved in resistance to ﬂuoroquinolone in
clinical isolates of E. faecalis. ABC transporter is an efﬂux pump described in
E. faecalis and its overexpression can confers resistance to ﬂuoroquinolones.
This is the ﬁrst report showing the presence of efﬂux pump genes efrAB in
Enterococcus spp. isolated from clinical samples in Iran. The use of ﬂuoroqui-
nolones as a feed additive in food animals might contribute to the increase and
distribution of efrAB to human. So, we suggest that the use of antibiotics should be
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carefully evaluated in poultry to avoid the emergence of bacterial resistance to
clinically relevant antibiotics.
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